There is no fulltext present in this item.

Find Full text  
Title: Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases
Author(s): Schellekens, A.F.A. ; Mulder, S.F. ; Eijndhoven, P.F.P. van ; Smilde, T.J. ; van Herpen, C.M.
Publication year: 2011
Source: General Hospital Psychiatry, vol. 33, iss. 1, (2011), pp. 83 e1-3
ISSN: 0163-8343
DOI: https://doi.org/10.1016/j.genhosppsych.2010.07.006
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/97276   https://hdl.handle.net/2066/97276

Display more details
Subject: DCN 1: Perception and Action
ONCOL 3: Translational research
Organization: Cognitive Neuroscience
Psychiatry
Medical Oncology
Anesthesiology
Internal Medicine
Journal title:
General Hospital Psychiatry
Volume: vol. 33
Issue: iss. 1
Page start: p. 83 e1
Page end: p. 3
Abstract:
The vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib is a first-line treatment in most patients with metastatic renal cell carcinoma. No psychiatric adverse events have previously been reported. We describe two patients with psychotic symptoms, during treatment with sunitinib. Possible mechanisms of sunitinib-induced psychosis are discussed.

This item appears in the following Collection(s)

Browse

Statistics